European Medicines Agency's CHMP recommends Dupixent (dupilumab), a targeted therapy for COPD, for EU approval.
European Medicines Agency's CHMP recommends Dupixent (dupilumab) for approval in EU as an add-on treatment for uncontrolled COPD with raised blood eosinophils. Developed by Regeneron Pharmaceuticals and Sanofi, it's the first targeted therapy for COPD in the EU and the first new treatment approach in over a decade. The EU Commission will announce a final decision in the coming months.
May 31, 2024
9 Articles